Ajanta Pharma views Research and Development as a vital component of business strategy
that will provide us with an competitive advantage. We recognize that ‘innovation
is the key to success’ and have been consistently investing in R&D over the last
Our R&D facility, ‘Advent’ has more than 300 diligent and committed scientists.
Based in Mumbai, Advent houses a range of state-of-the-art equipment for formulation
development, working on different dosage forms such as topical creams, ophthalmological
preparations, nasal sprays, solid orals, liquids and dry powder inhalers. We have an equally well equipped Active Pharmaceutical Ingredient(API) lab at
Advent to synthesize high value APIs for some of our key products. Many of the formulations
developed by our R&D are first of their kind and now hold leading positions in
their sub-therapeutic segments across different geographies.
The research centre primarily focuses on development of new formulations with an
objective to introduce first-to-market products providing convenience and
better patient compliance. We have been taking continuous initiatives towards technology
absorption, adaptation and innovation at Advent, resulting in the upgrade of all equipment to encompass latest technological developments in the field of research.
Our R&D hub covers an area of 30,000 sq feet (2,800 sq meters) and is fully equipped
with modern amenities and technology for accessing reference material, environmental
monitoring, data collection & analysis, record keeping and archiving.
Our team is provided with an environment that nurtures excellence and innovation
which is most essential to develop complex and challenging first-time combination
products and also first-to-launch generic products in our focus therapeutic segments.
The R&D team is completely involved in all projects from concept to Phase IV study
tracking market acceptability and after-launch status.
Few of our notable R&D achievements are in the segment of anti-malarial with our
flagship brand, Artefan - the first generic product to have been pre-qualified
by the World Health Organization (WHO), Geneva. Our other key brands include Kamagra
(Sildenafil Citrate) & Apcalis-SX (Tadalafil), both used in the treatment of Male
Erectile Dysfunction. These are available in the conventional tablet as well as
in an innovative "jelly" form which is the world's first of its kind dosage form
for this molecule.